Medifast (MED) Expected to Announce Earnings on Monday

03 May 2026, 01:08 by Jessica Moore · The Cerbat Gem

Medifast (NYSE:MED – Get Free Report) is expected to release its Q1 2026 results after the market closes on Monday, May 4th. Analysts expect Medifast to post earnings of ($0.55) per share and revenue of $69.20 million for the quarter. Medifast has set its FY 2026 guidance at -2.750–1.55 EPS and its Q1 2026 guidance at -0.700–0.15 EPS. Parties can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Monday, May 4, 2026 at 4:30 PM ET.

Medifast (NYSE:MED – Get Free Report) last issued its quarterly earnings results on Tuesday, February 17th. The specialty retailer reported ($0.55) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.21. The business had revenue of $75.10 million during the quarter, compared to analyst estimates of $71.40 million. Medifast had a negative net margin of 4.84% and a negative return on equity of 4.27%. On average, analysts expect Medifast to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Medifast Price Performance

Shares of Medifast stock opened at $10.91 on Friday. The firm has a market cap of $120.37 million, a P/E ratio of -6.38 and a beta of 0.55. The firm has a 50 day simple moving average of $10.41 and a 200 day simple moving average of $11.11. Medifast has a fifty-two week low of $9.22 and a fifty-two week high of $15.46.

Insider Buying and Selling

In other Medifast news, CEO Daniel R. Chard bought 17,678 shares of the stock in a transaction on Friday, March 20th. The stock was purchased at an average price of $10.11 per share, with a total value of $178,724.58. Following the acquisition, the chief executive officer owned 17,678 shares of the company’s stock, valued at approximately $178,724.58. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 3.70% of the company’s stock.

Institutional Trading of Medifast

A number of institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets grew its holdings in Medifast by 103.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,338 shares of the specialty retailer’s stock worth $32,000 after acquiring an additional 1,187 shares during the period. Man Group plc grew its holdings in shares of Medifast by 0.6% in the 2nd quarter. Man Group plc now owns 198,156 shares of the specialty retailer’s stock valued at $2,784,000 after buying an additional 1,200 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of Medifast by 2.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 53,341 shares of the specialty retailer’s stock valued at $749,000 after buying an additional 1,316 shares during the period. Barclays PLC grew its holdings in shares of Medifast by 10.6% in the 4th quarter. Barclays PLC now owns 16,769 shares of the specialty retailer’s stock valued at $179,000 after buying an additional 1,608 shares during the period. Finally, Quantbot Technologies LP acquired a new position in shares of Medifast in the 3rd quarter valued at $37,000. Institutional investors and hedge funds own 95.51% of the company’s stock.

Analysts Set New Price Targets

MED has been the subject of a number of research reports. Weiss Ratings reissued a “sell (d)” rating on shares of Medifast in a report on Thursday, January 22nd. Stephens lowered their target price on shares of Medifast from $15.00 to $12.00 and set an “equal weight” rating for the company in a report on Thursday, February 19th. Finally, Wall Street Zen raised shares of Medifast from a “sell” rating to a “hold” rating in a report on Saturday, March 21st. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Medifast presently has an average rating of “Reduce” and a consensus price target of $12.00.

Read Our Latest Stock Report on Medifast

Medifast Company Profile

(Get Free Report)

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.